

Global Long-acting Anti-HIV Drug Market Growth 2026-2032

<https://marketpublishers.com/r/G4BDE0746599EN.html>

Date: August 2026

Pages: 88

Price: US\$ 3,660.00 (Single User License)

ID: G4BDE0746599EN

Abstracts

The global Long-acting Anti-HIV Drug market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Long-acting anti-HIV drugs provide effective treatment options for HIV-infected people and have been widely recognized by the market. With the continuous deepening of research and development and the growth of market demand, long-acting anti-HIV drugs are expected to play a greater role in the future.

LP Information, Inc. (LPI) ' newest research report, the ?Long-acting Anti-HIV Drug Industry Forecast? looks at past sales and reviews total world Long-acting Anti-HIV Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting Anti-HIV Drug sales for 2026 through 2032. With Long-acting Anti-HIV Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Long-acting Anti-HIV Drug industry.

This Insight Report provides a comprehensive analysis of the global Long-acting Anti-HIV Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Anti-HIV Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Long-acting Anti-HIV Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Long-acting Anti-HIV Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Anti-HIV Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Anti-HIV Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

CAB Long-acting Injection

RPV Long-acting Injection

Segmentation by Application:

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered

from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Gilead

ViiV Healthcare

Janssen

Tibotec

Cipla

Frontier Biopharmaceutical (Nanjing) Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Long-acting Anti-HIV Drug market?

What factors are driving Long-acting Anti-HIV Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Long-acting Anti-HIV Drug market opportunities vary by end market size?

How does Long-acting Anti-HIV Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Long-acting Anti-HIV Drug Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Long-acting Anti-HIV Drug by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Long-acting Anti-HIV Drug by Country/Region, 2021, 2025 & 2032
- 2.2 Long-acting Anti-HIV Drug Segment by Type
 - 2.2.1 CAB Long-acting Injection
 - 2.2.2 RPV Long-acting Injection
 - 2.2.3 Long-acting Anti-HIV Drug Sales by Type
 - 2.2.3.1 Global Long-acting Anti-HIV Drug Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Long-acting Anti-HIV Drug Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Long-acting Anti-HIV Drug Sale Price by Type (2021-2026)
- 2.3 Long-acting Anti-HIV Drug Segment by Application
 - 2.3.1 Hospital
 - 2.3.2 Clinic
 - 2.3.3 Others
 - 2.3.4 Long-acting Anti-HIV Drug Sales by Application
 - 2.3.4.1 Global Long-acting Anti-HIV Drug Sale Market Share by Application (2021-2026)
 - 2.3.4.2 Global Long-acting Anti-HIV Drug Revenue and Market Share by Application (2021-2026)
 - 2.3.4.3 Global Long-acting Anti-HIV Drug Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Long-acting Anti-HIV Drug Breakdown Data by Company

3.1.1 Global Long-acting Anti-HIV Drug Annual Sales by Company (2021-2026)

3.1.2 Global Long-acting Anti-HIV Drug Sales Market Share by Company (2021-2026)

3.2 Global Long-acting Anti-HIV Drug Annual Revenue by Company (2021-2026)

3.2.1 Global Long-acting Anti-HIV Drug Revenue by Company (2021-2026)

3.2.2 Global Long-acting Anti-HIV Drug Revenue Market Share by Company (2021-2026)

3.3 Global Long-acting Anti-HIV Drug Sale Price by Company

3.4 Key Manufacturers Long-acting Anti-HIV Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Long-acting Anti-HIV Drug Product Location Distribution

3.4.2 Players Long-acting Anti-HIV Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LONG-ACTING ANTI-HIV DRUG BY GEOGRAPHIC REGION

4.1 World Historic Long-acting Anti-HIV Drug Market Size by Geographic Region (2021-2026)

4.1.1 Global Long-acting Anti-HIV Drug Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Long-acting Anti-HIV Drug Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Long-acting Anti-HIV Drug Market Size by Country/Region (2021-2026)

4.2.1 Global Long-acting Anti-HIV Drug Annual Sales by Country/Region (2021-2026)

4.2.2 Global Long-acting Anti-HIV Drug Annual Revenue by Country/Region (2021-2026)

4.3 Americas Long-acting Anti-HIV Drug Sales Growth

4.4 APAC Long-acting Anti-HIV Drug Sales Growth

4.5 Europe Long-acting Anti-HIV Drug Sales Growth

4.6 Middle East & Africa Long-acting Anti-HIV Drug Sales Growth

5 AMERICAS

5.1 Americas Long-acting Anti-HIV Drug Sales by Country

5.1.1 Americas Long-acting Anti-HIV Drug Sales by Country (2021-2026)

5.1.2 Americas Long-acting Anti-HIV Drug Revenue by Country (2021-2026)

5.2 Americas Long-acting Anti-HIV Drug Sales by Type (2021-2026)

5.3 Americas Long-acting Anti-HIV Drug Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Long-acting Anti-HIV Drug Sales by Region

6.1.1 APAC Long-acting Anti-HIV Drug Sales by Region (2021-2026)

6.1.2 APAC Long-acting Anti-HIV Drug Revenue by Region (2021-2026)

6.2 APAC Long-acting Anti-HIV Drug Sales by Type (2021-2026)

6.3 APAC Long-acting Anti-HIV Drug Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Long-acting Anti-HIV Drug by Country

7.1.1 Europe Long-acting Anti-HIV Drug Sales by Country (2021-2026)

7.1.2 Europe Long-acting Anti-HIV Drug Revenue by Country (2021-2026)

7.2 Europe Long-acting Anti-HIV Drug Sales by Type (2021-2026)

7.3 Europe Long-acting Anti-HIV Drug Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Long-acting Anti-HIV Drug by Country

8.1.1 Middle East & Africa Long-acting Anti-HIV Drug Sales by Country (2021-2026)

8.1.2 Middle East & Africa Long-acting Anti-HIV Drug Revenue by Country (2021-2026)

8.2 Middle East & Africa Long-acting Anti-HIV Drug Sales by Type (2021-2026)

8.3 Middle East & Africa Long-acting Anti-HIV Drug Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drug

10.3 Manufacturing Process Analysis of Long-acting Anti-HIV Drug

10.4 Industry Chain Structure of Long-acting Anti-HIV Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Long-acting Anti-HIV Drug Distributors

11.3 Long-acting Anti-HIV Drug Customer

12 WORLD FORECAST REVIEW FOR LONG-ACTING ANTI-HIV DRUG BY GEOGRAPHIC REGION

- 12.1 Global Long-acting Anti-HIV Drug Market Size Forecast by Region
 - 12.1.1 Global Long-acting Anti-HIV Drug Forecast by Region (2027-2032)
 - 12.1.2 Global Long-acting Anti-HIV Drug Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Long-acting Anti-HIV Drug Forecast by Type (2027-2032)
- 12.7 Global Long-acting Anti-HIV Drug Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 Gilead
 - 13.1.1 Gilead Company Information
 - 13.1.2 Gilead Long-acting Anti-HIV Drug Product Portfolios and Specifications
 - 13.1.3 Gilead Long-acting Anti-HIV Drug Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 Gilead Main Business Overview
 - 13.1.5 Gilead Latest Developments
- 13.2 ViiV Healthcare
 - 13.2.1 ViiV Healthcare Company Information
 - 13.2.2 ViiV Healthcare Long-acting Anti-HIV Drug Product Portfolios and Specifications
 - 13.2.3 ViiV Healthcare Long-acting Anti-HIV Drug Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 ViiV Healthcare Main Business Overview
 - 13.2.5 ViiV Healthcare Latest Developments
- 13.3 Janssen
 - 13.3.1 Janssen Company Information
 - 13.3.2 Janssen Long-acting Anti-HIV Drug Product Portfolios and Specifications
 - 13.3.3 Janssen Long-acting Anti-HIV Drug Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Janssen Main Business Overview
 - 13.3.5 Janssen Latest Developments
- 13.4 Tibotec
 - 13.4.1 Tibotec Company Information
 - 13.4.2 Tibotec Long-acting Anti-HIV Drug Product Portfolios and Specifications

13.4.3 Tibotec Long-acting Anti-HIV Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Tibotec Main Business Overview

13.4.5 Tibotec Latest Developments

13.5 Cipla

13.5.1 Cipla Company Information

13.5.2 Cipla Long-acting Anti-HIV Drug Product Portfolios and Specifications

13.5.3 Cipla Long-acting Anti-HIV Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Cipla Main Business Overview

13.5.5 Cipla Latest Developments

13.6 Frontier Biopharmaceutical (Nanjing) Co., Ltd.

13.6.1 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Company Information

13.6.2 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product Portfolios and Specifications

13.6.3 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Main Business Overview

13.6.5 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Long-acting Anti-HIV Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Long-acting Anti-HIV Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of CAB Long-acting Injection
- Table 4. Major Players of RPV Long-acting Injection
- Table 5. Global Long-acting Anti-HIV Drug Sales by Type (2021-2026) & (K Units)
- Table 6. Global Long-acting Anti-HIV Drug Sales Market Share by Type (2021-2026)
- Table 7. Global Long-acting Anti-HIV Drug Revenue by Type (2021-2026) & (\$ million)
- Table 8. Global Long-acting Anti-HIV Drug Revenue Market Share by Type (2021-2026)
- Table 9. Global Long-acting Anti-HIV Drug Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 10. Global Long-acting Anti-HIV Drug Sale by Application (2021-2026) & (K Units)
- Table 11. Global Long-acting Anti-HIV Drug Sale Market Share by Application (2021-2026)
- Table 12. Global Long-acting Anti-HIV Drug Revenue by Application (2021-2026) & (\$ million)
- Table 13. Global Long-acting Anti-HIV Drug Revenue Market Share by Application (2021-2026)
- Table 14. Global Long-acting Anti-HIV Drug Sale Price by Application (2021-2026) & (US\$/Unit)
- Table 15. Global Long-acting Anti-HIV Drug Sales by Company (2021-2026) & (K Units)
- Table 16. Global Long-acting Anti-HIV Drug Sales Market Share by Company (2021-2026)
- Table 17. Global Long-acting Anti-HIV Drug Revenue by Company (2021-2026) & (\$ millions)
- Table 18. Global Long-acting Anti-HIV Drug Revenue Market Share by Company (2021-2026)
- Table 19. Global Long-acting Anti-HIV Drug Sale Price by Company (2021-2026) & (US\$/Unit)
- Table 20. Key Manufacturers Long-acting Anti-HIV Drug Producing Area Distribution and Sales Area
- Table 21. Players Long-acting Anti-HIV Drug Products Offered
- Table 22. Long-acting Anti-HIV Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Long-acting Anti-HIV Drug Sales by Geographic Region (2021-2026) & (K Units)

Table 26. Global Long-acting Anti-HIV Drug Sales Market Share Geographic Region (2021-2026)

Table 27. Global Long-acting Anti-HIV Drug Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 28. Global Long-acting Anti-HIV Drug Revenue Market Share by Geographic Region (2021-2026)

Table 29. Global Long-acting Anti-HIV Drug Sales by Country/Region (2021-2026) & (K Units)

Table 30. Global Long-acting Anti-HIV Drug Sales Market Share by Country/Region (2021-2026)

Table 31. Global Long-acting Anti-HIV Drug Revenue by Country/Region (2021-2026) & (\$ millions)

Table 32. Global Long-acting Anti-HIV Drug Revenue Market Share by Country/Region (2021-2026)

Table 33. Americas Long-acting Anti-HIV Drug Sales by Country (2021-2026) & (K Units)

Table 34. Americas Long-acting Anti-HIV Drug Sales Market Share by Country (2021-2026)

Table 35. Americas Long-acting Anti-HIV Drug Revenue by Country (2021-2026) & (\$ millions)

Table 36. Americas Long-acting Anti-HIV Drug Sales by Type (2021-2026) & (K Units)

Table 37. Americas Long-acting Anti-HIV Drug Sales by Application (2021-2026) & (K Units)

Table 38. APAC Long-acting Anti-HIV Drug Sales by Region (2021-2026) & (K Units)

Table 39. APAC Long-acting Anti-HIV Drug Sales Market Share by Region (2021-2026)

Table 40. APAC Long-acting Anti-HIV Drug Revenue by Region (2021-2026) & (\$ millions)

Table 41. APAC Long-acting Anti-HIV Drug Sales by Type (2021-2026) & (K Units)

Table 42. APAC Long-acting Anti-HIV Drug Sales by Application (2021-2026) & (K Units)

Table 43. Europe Long-acting Anti-HIV Drug Sales by Country (2021-2026) & (K Units)

Table 44. Europe Long-acting Anti-HIV Drug Revenue by Country (2021-2026) & (\$ millions)

Table 45. Europe Long-acting Anti-HIV Drug Sales by Type (2021-2026) & (K Units)

Table 46. Europe Long-acting Anti-HIV Drug Sales by Application (2021-2026) & (K

Units)

Table 47. Middle East & Africa Long-acting Anti-HIV Drug Sales by Country (2021-2026) & (K Units)

Table 48. Middle East & Africa Long-acting Anti-HIV Drug Revenue Market Share by Country (2021-2026)

Table 49. Middle East & Africa Long-acting Anti-HIV Drug Sales by Type (2021-2026) & (K Units)

Table 50. Middle East & Africa Long-acting Anti-HIV Drug Sales by Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Long-acting Anti-HIV Drug

Table 52. Key Market Challenges & Risks of Long-acting Anti-HIV Drug

Table 53. Key Industry Trends of Long-acting Anti-HIV Drug

Table 54. Long-acting Anti-HIV Drug Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Long-acting Anti-HIV Drug Distributors List

Table 57. Long-acting Anti-HIV Drug Customer List

Table 58. Global Long-acting Anti-HIV Drug Sales Forecast by Region (2027-2032) & (K Units)

Table 59. Global Long-acting Anti-HIV Drug Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 60. Americas Long-acting Anti-HIV Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 61. Americas Long-acting Anti-HIV Drug Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC Long-acting Anti-HIV Drug Sales Forecast by Region (2027-2032) & (K Units)

Table 63. APAC Long-acting Anti-HIV Drug Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe Long-acting Anti-HIV Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe Long-acting Anti-HIV Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa Long-acting Anti-HIV Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa Long-acting Anti-HIV Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global Long-acting Anti-HIV Drug Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global Long-acting Anti-HIV Drug Revenue Forecast by Type (2027-2032) &

(\$ millions)

Table 70. Global Long-acting Anti-HIV Drug Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global Long-acting Anti-HIV Drug Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Gilead Basic Information, Long-acting Anti-HIV Drug Manufacturing Base, Sales Area and Its Competitors

Table 73. Gilead Long-acting Anti-HIV Drug Product Portfolios and Specifications

Table 74. Gilead Long-acting Anti-HIV Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Gilead Main Business

Table 76. Gilead Latest Developments

Table 77. ViiV Healthcare Basic Information, Long-acting Anti-HIV Drug Manufacturing Base, Sales Area and Its Competitors

Table 78. ViiV Healthcare Long-acting Anti-HIV Drug Product Portfolios and Specifications

Table 79. ViiV Healthcare Long-acting Anti-HIV Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. ViiV Healthcare Main Business

Table 81. ViiV Healthcare Latest Developments

Table 82. Janssen Basic Information, Long-acting Anti-HIV Drug Manufacturing Base, Sales Area and Its Competitors

Table 83. Janssen Long-acting Anti-HIV Drug Product Portfolios and Specifications

Table 84. Janssen Long-acting Anti-HIV Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. Janssen Main Business

Table 86. Janssen Latest Developments

Table 87. Tibotec Basic Information, Long-acting Anti-HIV Drug Manufacturing Base, Sales Area and Its Competitors

Table 88. Tibotec Long-acting Anti-HIV Drug Product Portfolios and Specifications

Table 89. Tibotec Long-acting Anti-HIV Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. Tibotec Main Business

Table 91. Tibotec Latest Developments

Table 92. Cipla Basic Information, Long-acting Anti-HIV Drug Manufacturing Base, Sales Area and Its Competitors

Table 93. Cipla Long-acting Anti-HIV Drug Product Portfolios and Specifications

Table 94. Cipla Long-acting Anti-HIV Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Cipla Main Business

Table 96. Cipla Latest Developments

Table 97. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Basic Information, Long-acting Anti-HIV Drug Manufacturing Base, Sales Area and Its Competitors

Table 98. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product Portfolios and Specifications

Table 99. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Main Business

Table 101. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Long-acting Anti-HIV Drug
- Figure 2. Long-acting Anti-HIV Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Long-acting Anti-HIV Drug Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Long-acting Anti-HIV Drug Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Long-acting Anti-HIV Drug Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Long-acting Anti-HIV Drug Sales Market Share by Country/Region (2025)
- Figure 10. Long-acting Anti-HIV Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of CAB Long-acting Injection
- Figure 12. Product Picture of RPV Long-acting Injection
- Figure 13. Global Long-acting Anti-HIV Drug Sales Market Share by Type in 2026
- Figure 14. Global Long-acting Anti-HIV Drug Revenue Market Share by Type (2021-2026)
- Figure 15. Long-acting Anti-HIV Drug Consumed in Hospital
- Figure 16. Global Long-acting Anti-HIV Drug Market: Hospital (2021-2026) & (K Units)
- Figure 17. Long-acting Anti-HIV Drug Consumed in Clinic
- Figure 18. Global Long-acting Anti-HIV Drug Market: Clinic (2021-2026) & (K Units)
- Figure 19. Long-acting Anti-HIV Drug Consumed in Others
- Figure 20. Global Long-acting Anti-HIV Drug Market: Others (2021-2026) & (K Units)
- Figure 21. Global Long-acting Anti-HIV Drug Sale Market Share by Application (2025)
- Figure 22. Global Long-acting Anti-HIV Drug Revenue Market Share by Application in 2026
- Figure 23. Long-acting Anti-HIV Drug Sales by Company in 2026 (K Units)
- Figure 24. Global Long-acting Anti-HIV Drug Sales Market Share by Company in 2026
- Figure 25. Long-acting Anti-HIV Drug Revenue by Company in 2026 (\$ millions)
- Figure 26. Global Long-acting Anti-HIV Drug Revenue Market Share by Company in 2026
- Figure 27. Global Long-acting Anti-HIV Drug Sales Market Share by Geographic Region (2021-2026)
- Figure 28. Global Long-acting Anti-HIV Drug Revenue Market Share by Geographic

Region in 2026

Figure 29. Americas Long-acting Anti-HIV Drug Sales 2021-2026 (K Units)

Figure 30. Americas Long-acting Anti-HIV Drug Revenue 2021-2026 (\$ millions)

Figure 31. APAC Long-acting Anti-HIV Drug Sales 2021-2026 (K Units)

Figure 32. APAC Long-acting Anti-HIV Drug Revenue 2021-2026 (\$ millions)

Figure 33. Europe Long-acting Anti-HIV Drug Sales 2021-2026 (K Units)

Figure 34. Europe Long-acting Anti-HIV Drug Revenue 2021-2026 (\$ millions)

Figure 35. Middle East & Africa Long-acting Anti-HIV Drug Sales 2021-2026 (K Units)

Figure 36. Middle East & Africa Long-acting Anti-HIV Drug Revenue 2021-2026 (\$ millions)

Figure 37. Americas Long-acting Anti-HIV Drug Sales Market Share by Country in 2026

Figure 38. Americas Long-acting Anti-HIV Drug Revenue Market Share by Country (2021-2026)

Figure 39. Americas Long-acting Anti-HIV Drug Sales Market Share by Type (2021-2026)

Figure 40. Americas Long-acting Anti-HIV Drug Sales Market Share by Application (2021-2026)

Figure 41. United States Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 42. Canada Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 43. Mexico Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 44. Brazil Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 45. APAC Long-acting Anti-HIV Drug Sales Market Share by Region in 2026

Figure 46. APAC Long-acting Anti-HIV Drug Revenue Market Share by Region (2021-2026)

Figure 47. APAC Long-acting Anti-HIV Drug Sales Market Share by Type (2021-2026)

Figure 48. APAC Long-acting Anti-HIV Drug Sales Market Share by Application (2021-2026)

Figure 49. China Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 50. Japan Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 51. South Korea Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 52. Southeast Asia Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 53. India Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 54. Australia Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 55. China Taiwan Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 56. Europe Long-acting Anti-HIV Drug Sales Market Share by Country in 2026

Figure 57. Europe Long-acting Anti-HIV Drug Revenue Market Share by Country (2021-2026)

Figure 58. Europe Long-acting Anti-HIV Drug Sales Market Share by Type (2021-2026)

Figure 59. Europe Long-acting Anti-HIV Drug Sales Market Share by Application (2021-2026)

Figure 60. Germany Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 61. France Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 62. UK Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 63. Italy Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 64. Russia Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 65. Middle East & Africa Long-acting Anti-HIV Drug Sales Market Share by Country (2021-2026)

Figure 66. Middle East & Africa Long-acting Anti-HIV Drug Sales Market Share by Type (2021-2026)

Figure 67. Middle East & Africa Long-acting Anti-HIV Drug Sales Market Share by Application (2021-2026)

Figure 68. Egypt Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 69. South Africa Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 70. Israel Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 71. Turkey Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 72. GCC Countries Long-acting Anti-HIV Drug Revenue Growth 2021-2026 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drug in 2026

Figure 74. Manufacturing Process Analysis of Long-acting Anti-HIV Drug

Figure 75. Industry Chain Structure of Long-acting Anti-HIV Drug

Figure 76. Channels of Distribution

Figure 77. Global Long-acting Anti-HIV Drug Sales Market Forecast by Region (2027-2032)

Figure 78. Global Long-acting Anti-HIV Drug Revenue Market Share Forecast by Region (2027-2032)

Figure 79. Global Long-acting Anti-HIV Drug Sales Market Share Forecast by Type (2027-2032)

Figure 80. Global Long-acting Anti-HIV Drug Revenue Market Share Forecast by Type (2027-2032)

Figure 81. Global Long-acting Anti-HIV Drug Sales Market Share Forecast by Application (2027-2032)

Figure 82. Global Long-acting Anti-HIV Drug Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Long-acting Anti-HIV Drug Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G4BDE0746599EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4BDE0746599EN.html>